Comprehensive Drug Information for Smith, John
|
|
- Cori Woods
- 5 years ago
- Views:
Transcription
1 PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI Source: Buccal Swabs Comprehensive Drug Information for Smith, John ICD-10: I10 Essential (primary) hypertension; I25.10 Athscl heart disease of native coronary artery w/o ang pctrs Admera Health, LLC REFERRING PHYSICIAN Name: Jane Doe, MD Institution: Local Hospital Atorvastatin (Lipitor ) Metoprolol (Lopressor ) by 50% Lovastatin (Mevacor ) Simvastatin (Zocor ) Atorvastatin (Lipitor ) Lovastatin (Mevacor ) to lowest necessary dose daily Ivabradine (Corlentor ) Simvastatin (Zocor ) Metoprolol (Lopressor ) Ticagrelor (Brilinta ) Warfarin (Coumadin ) NORMAL DOSE Warfarin daily dose 5-7mg Amlodipine (Norvasc ) Atenolol (Tenormin ) Diltiazem (Cardizem ) Carvedilol (Coreg ) Felodipine (Plendil ) Clopidogrel (Plavix ) Lercanidipine (Zanidip ) Phenprocoumon (Marcoumar ) Nifedipine (Adalat ) Nisoldipine (Sular ) Only selected drugs are listed here due to limited space. Please refer to Patient Specific Genotype Results table for comprehensive illustration of drugs in each action category. PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 1 of 11
2 Patient Specific Genotype Results and Comprehensive Drug Information for Smith, John ICD-10: I10 Essential (primary) hypertension;i25.10 Athscl heart disease of native coronary artery w/o ang pctrs Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Antianginal Drugs: Ivabradine (Corlentor ) CYP3A4 *1B/*1B Poor Antiplatelets: Ticagrelor (Brilinta ) CYP3A4 *1B/*1B Poor Metoprolol (Lopressor ) Atorvastatin (Lipitor ), Lovastatin (Mevacor ), Simvastatin (Zocor ) Rivaroxaban (Xarelto ) Calcium Channel Blockers: Amlodipine (Norvasc ), Diltiazem (Cardizem ), Felodipine (Plendil ), Lercanidipine (Zanidip ), Nifedipine (Adalat ), Nisoldipine (Sular ), Nitrendipine (Nitrepin ), Verapamil (Calan ) Antianginal Drugs: Ranolazine (Ranexa ) (e.g., bisoprolol, carvedilol) OR by 50% due to heart failure caused by the decreased drug cardioselectivity (e.g., pitavastatin, pravastatin, rosuvastatin) OR to lowest necessary dose daily due to Increased risk for myopathy and rhabdomyolysis due to increased bleeding risk due to significant increase in drug exposure and therefore clinical monitoring and dose adjustment may thus be required CYP2D6 *10/*41 Intermediate CYP3A4 *1B/*1B Poor CYP3A4 *1B/*1B Poor CYP3A4 *1B/*1B Poor CYP2D6 *10/*41 Intermediate PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 2 of 11
3 Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Phenprocoumon (Marcoumar ) CYP4F2 *1/*1 Normal Warfarin (Coumadin ) NORMAL DOSE Warfarin daily dose 5-7mg CYP2C9 *1/*1 Normal Warfarin (Coumadin ) NORMAL DOSE Warfarin daily dose 5-7mg VKORC1 WT/-1639G>A rs A Allele Carrier Antiplatelets: Clopidogrel (Plavix ) CYP2C19 *1/*17 Ultrarapid Atenolol (Tenormin ) LDLR WT/c.*773A>G rs G Allele Carrier Carvedilol (Coreg ) CYP2D6 *10/*41 Intermediate Pitavastatin (Livalo ), Pravastatin (Pravachol ), Rosuvastatin (Crestor ) SLCO1B1 *1/*1 Normal Activity PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 3 of 11
4 Current Medication Information for Smith, John Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Metoprolol (e.g., bisoprolol, carvedilol) OR CYP2D6 *10/*41 Intermediate Calcium Channel Blockers: Norvasc Crestor by 50% due to heart failure caused by the decreased drug cardioselectivity due to significant increase in drug exposure and therefore clinical monitoring and dose adjustment may thus be required CYP3A4 *1B/*1B Poor SLCO1B1 *1/*1 Normal Activity Analgesic: Aspir 81 CLINICAL EVIDENCE NOT SUFFICIENT CYP2D6 *10/*41 Intermediate Vitamins: Niacin CLINICAL INTERPRETATION NOT AVAILABLE NA NA NA PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 4 of 11
5 Drug-Drug Interactions for Smith, John Severity Drugs Warning Documentation Clinical Management Rosuvastatin -- Niacin Metoprolol -- Aspir 81 MAJOR Concurrent use of ROSUVASTATIN and NIACIN may result in an increased risk of myopathy or rhabdomyolysis. MODERATE Concurrent use of BETA- ADRENERGIC BLOCKERS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in decreased antihypertensive effect. Good Good Weigh the benefit of further alteration in lipid levels relative to the increased risk of this combination of agents. If concurrent therapy is required, monitor the patient for signs and symptoms of myopathy or rhabdomyolysis (muscle pain, tenderness, or weakness). Periodic CK determinations may be advisable in patients who are just starting or are increasing their dose of rosuvastatin, and in patients with complicated medical histories. Discontinue use if CK levels show a marked increase, or if myopathy or rhabdomyolysis is diagnosed or suspected. Use caution if an NSAID and a beta-adrenergic blocker are coadministered (Prod Info VIMOVO(TM) delayed release oral tablets, 2010). If concurrent therapy is required, monitor the patient's blood pressure carefully and assess the need for a dosage adjustment of the beta-blocker. PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 5 of 11
6 Portable Patient PGxCardio Genotype Results and Drug Information by Specialty for Smith, John Therapeutic Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Antianginal Drugs: Ivabradine (Corlentor ) CYP3A4 *1B/*1B Poor Antiarrhythmic Drugs: Amiodarone (Cordarone ), Dronedarone (Multaq ) Antiarrhythmic Drugs: Propafenone (Rythmol ) Antiplatelets: Ticagrelor (Brilinta ) CYP3A4 *1B/*1B Poor CYP2D6 *10/*41 Intermediate (e.g., sotalol, disopyramide, quinidine, amiodarone) CYP3A4 *1B/*1B Poor Metoprolol (Lopressor ) (e.g., bisoprolol, carvedilol) CYP2D6 *10/*41 Intermediate OR by 50% due to heart failure caused by the decreased drug cardioselectivity Atorvastatin (Lipitor ), Lovastatin (Mevacor ), Simvastatin (Zocor ) (e.g., pitavastatin, pravastatin, rosuvastatin) OR CYP3A4 *1B/*1B Poor to lowest necessary dose daily due to Increased risk for myopathy and rhabdomyolysis Antiarrhythmic Drugs: Flecainide (Tambocor ) by 25% CYP2D6 *10/*41 Intermediate Phosphodiesterase Inhibitors: Cilostazol (Pletal ) by 50% CYP3A4 *1B/*1B Poor Rivaroxaban (Xarelto ) due to increased bleeding risk CYP3A4 *1B/*1B Poor PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 6 of 11
7 Therapeutic Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Calcium Channel CYP3A4 *1B/*1B Poor Blockers: due to significant increase in Amlodipine (Norvasc ), Diltiazem (Cardizem ), Felodipine (Plendil ), drug exposure and therefore clinical monitoring and dose adjustment may thus be Lercanidipine (Zanidip ), required Nifedipine (Adalat ), Nisoldipine (Sular ), Nitrendipine (Nitrepin ), Verapamil (Calan ) Atorvastatin (Lipitor ), Lovastatin (Mevacor ), Simvastatin (Zocor ) due to impaired efficacy CYP3A5 *1A/*1A High Expresser Antianginal Drugs: CYP2D6 *10/*41 Intermediate Ranolazine (Ranexa ) Phenprocoumon (Marcoumar ) CYP4F2 *1/*1 Normal Warfarin (Coumadin ) NORMAL DOSE Warfarin daily dose 5-7mg CYP2C9 *1/*1 Normal Warfarin (Coumadin ) NORMAL DOSE Warfarin daily dose 5-7mg VKORC1 WT/-1639G>A rs A Allele Carrier Antiplatelets: Clopidogrel (Plavix ) CYP2C19 *1/*17 Ultrarapid Atenolol (Tenormin ) LDLR WT/c.*773A> G rs G Allele Carrier Carvedilol (Coreg ) CYP2D6 *10/*41 Intermediate Pitavastatin (Livalo ), Pravastatin (Pravachol ), Rosuvastatin (Crestor ) Simvastatin (Zocor ) SLCO1B1 *1/*1 Normal Activity SLCO1B1 *1/*1 Normal Activity PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 7 of 11
8 Patient PGxCardio Genotype and Phenotype Results for Smith, John Gene Genotype Phenotype CYP2C19 *1/*17 Ultrarapid CYP2C9 *1/*1 Normal CYP2D6 *10/*41 Intermediate CYP3A4 *1B/*1B Poor CYP3A5 *1A/*1A High Expresser CYP4F2 *1/*1 Normal LDLR WT/c.*773A>G rs G Allele Carrier SLCO1B1 *1/*1 Normal Activity VKORC1 WT/-1639G>A rs A Allele Carrier PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 8 of 11
9 PGxCardio Panel Genes and Variants: This test only detects those genes and variants listed below. A normal (wild type) genotype signifies the absence of the targeted alleles and does not indicate the absence of other mutations not covered by the assay. The possibility cannot be ruled out that the indicated genotypes may be present but below the limits of detection for this assay. The panel includes 9 genes and 68 variants based on the recommendations of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) and the FDA s work group guidance. Gene Allele Type Alleles CYP2C19 CYP2C9 CYP2D6 CYP3A4 CYP3A5 CYP4F2 LDLR Increased Activity Inactive Inactive Inactive Deletion Amplification Inactive *1 *17 *9, *10 *2, *3, *4, *5, *6, *7, *8, *12 *1 *2, *3, *4, *5, *8, *9, *11, *12, *13, *14, *16 *6, *15 *1, *2, *35, *9, *10, *17, *29, *36, *41 *3, *4, *6, *7, *8, *11, *12, *14, *15, *19, *20, *40 *5 *1XN, *2XN, *4XN, *10XN, *17XN, *41XN *1A *1B, *2, *3, *12, *17 *1A *1D, *2, *7, *8, *9 *3A, *3B, *6 *1 *3 rs688 SLCO1B1 *5 VKORC1 Increased Warfarin Sensitivity -1639G>A PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 9 of 11
10 Assay Methodology and Limitations for PGxCardio Panel: Pharmacogenomics testing to assess how a patient may respond to prescribed drugs was performed by massively parallel Next Generation Sequencing (NGS). PGxCardio was developed, and assessed for accuracy and precision by Admera Health, South Plainfield NJ. The sensitivity and specificity of this test is 100% and 100% respectively. PGxCardio has not been cleared or approved by the U.S. Food and Drug Administration (FDA) but the FDA has determined that such clearance or approval is not necessary. The PGxCardio test is used for clinical purposes. It should not be regarded as investigational or for research. Drug interaction information is based upon data available in scientific literature and prescribing information for the most commonly prescribed drugs. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. The DNA testing is not a substitute for clinical monitoring. Warnings & Precautions for PGxCardio Recommended Drugs: Atenolol (Tenormin ): Carvedilol (Coreg ): Clopidogrel (Plavix ): Pitavastatin (Livalo ): Pravastatin (Pravachol ): Ranolazine (Ranexa ): Rosuvastatin (Crestor ): Warfarin (Coumadin ): General Pharmacogenomics References: 1. Drug labels with pharmacogenomics information: 2. Pharmacogenomics drug dosing guidelines: 3. FDA Orange Book Search Engine: PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 10 of 11
11 Disclaimer of Liability: The information contained in this report is provided as a service and does not constitute medical advice. At the time of report generation this information is believed to be current and is based upon published research; however, research data evolves and amendments to the prescribing information of the drugs listed will change over time. While this report is believed to be accurate and complete as of the date issued, THE DATA IS PROVIDED "AS IS", WITHOUT WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. As medical advice must be tailored to the specific circumstances of each case, the treating health care professional has ultimate responsibility for all treatment decisions made with regard to a patient including any made on the basis of a patient's genotype. Electronic Signature Laboratory Director ABMG Certified, Clinical Molecular Genetics PGxCardio Report for Smith, John Laboratory Director: Dr. James Dermody CLIS ID: CLIA ID: 31D Page 11 of 11
Dynamic DNA Laboratories, LLC - DO NOT DISTRIBUTE
Cardiovascular Pharmacogenetic Report Created for: Patty Pain Patient: Patty Pain DOB: 1/1/1970 Accession #: 988889 SSN: Collection Date: Received Date: Ordering Physician: Report Generated: 1/28/2016
More informationPATIENT INFORMATION Name: Smith, Jill DOB: April 22, 1973 Age: 43 Sex: Female Address: 126 Corporate Blvd. South Plainfield, NJ SAMPLE REPORT SA
PATIENT INFORMATION Name: Smith, Jill DOB: April 22, 1973 Age: 43 Sex: Female Address: 126 Corporate Blvd. South Plainfield, NJ 07080 SAMPLE Date Collected: April 29, 2016 Date Received: April 29, 2016
More informationPatient Specific Genotype Results and Comprehensive Drug Information for Smith, John ICD-10: E78.5 Hyperlipidemia, unspecified;e87.5 Hyperkalemia;I21.
PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 43 Sex: Male Address: 126 Corporate Blvd. South Plainfield, NJ 07080 SAMPLE REPORT SAMPLE Date Collected: November 1, 2016 Date Received:
More informationAtrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.
Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:
More informationCardiovascular Pharmacogenetic Genotyping Panel
Cardiovascular Pharmacogenetic Genotyping Panel Table of Contents ABOUT THE TEST... 2 INDICATIONS... 2 TURNAROUND TIME... 2 MEDICATION LIST... 4 About the test Pharmacogenetics is the study of genetic
More informationPassAssured's Pharmacy Technician Training Systems. Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cardiovascular Drugs Pharmacy Technician Training Systems Passassured, LLC p1 Medication Review, Cardiovascular Drugs Click Here for Glossary Index! Click Here to Print Topic Help File
More informationTable 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents* Cardiac Drug(s) Enzyme/ Action Chemotherapy Drug Effect of Drug- Drug Interaction Suggested Oncologist Management Suggested
More informationChapter / Section / Drug
2 Cardiovascular System 2.1 Positive inotropic drugs Digoxin Digoxin specific antibody ( DigiFab ) 2.2 Diuretics 2.2.1 Thiazides and related diuretics Indapamide (1 st Line) Bendroflumethiazide Metolazone
More informationClinical Policy: Ranolazine (Ranexa) Reference Number: CP.PMN.34 Effective Date: Last Review Date: 02.19
Clinical Policy: (Ranexa) Reference Number: CP.PMN.34 Effective Date: 08.01.09 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCARDIAC IMAGING QUESTIONNAIRE
Date of test: / / Month day year Last name First name Middle initial Street address City State Zip code Home phone ( ) - Work phone ( ) - Cell Phone ( ) - Email: Age: Demographics: What is your ethnicity?
More informationInformation in these slides is used with permission from St. Mary s Cardiac Rehab
Information in these slides is used with permission from St. Mary s Cardiac Rehab Prescription Pointers Heart Medications Questions!! 2-4% of patients who visit ER s have experienced a medication misadventure
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationSLCO1B1 Pharmacogenetic Competency
SLCO1B1 Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Which of the following is not currently a recognized SLCO1B1 phenotype? a) Low function b) Normal function c) Intermediate function
More informationMedications for Treating Stroke
Medications for Treating Stroke Subject Expert Sonny Kupniewski, PharmD, BCPS Swedish Medical Center Englewood, CO 2 Objectives Medications used to prevent stroke Prevention of strokes in patients with
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationCardiac Medications At A Glance
Cardiac Medications At A Glance 1) Anticoagulants (Also known as Blood Thinners.) Dalteparin (Fragmin), Danaparoid (Orgaran) Enoxaparin (Lovenox) Heparin (various) Tinzaparin (Innohep) Warfarin (Coumadin)
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationMedications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy.
Medications Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy. What do I need to know about medications after my heart attack? When you
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Caduet) Reference Number: CP.CPA.237 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationPAIN MEDICATION DNA INSIGHT
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya, M.D. PAIN MEDICATION DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROESSIONAL Nilesh
More informationSimvastatin 40 mg equivalent
Simvastatin 40 mg equivalent medications equivalent to Simvastatin is available on the Drugs.com website. Simvastatin (Zocor ): 10 mg : Equivalent Dosages - 3: Atorvastatin (Lipitor. 40 mg : Equivalent
More informationCardiovascular Health. Heart Disease / Atrial Fibrillation. Hypertension
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR#:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More informationJay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center
Jay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center A-Fib Facts Yes, you may be able to blame your parents It is more of a nuisance than a
More informationImproving Health Literacy through Innovative Health Communication Tools
Improving Health Literacy through Innovative Health Communication Tools David W. Baker, MD, MPH Chief, General Internal Medicine Institute for Healthcare Studies Feinberg School of Medicine, Northwestern
More informationDeliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing
GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:
More informationCardiovascular pharmacogenomics: ready for prime time?
Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationMedicines for Heart Disease
Medicines for Heart Disease There are many medicines to treat heart disease. Ask your doctor, nurse, or pharmacist if you have questions about your medicines. Take medicines as directed. Do NOT stop taking
More informationQuality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care
Quality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationPharmacogenomics of Cardiovascular Pharmacotherapies
Pharmacogenomics of Cardiovascular Pharmacotherapies Rhonda M. Cooper-DeHoff, Pharm.D., M.S., FCCP, FACC, FAHA University of Florida Gainesville, Florida Pharmacogenomics of Cardiovascular Pharmacotherapies
More informationREVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationChapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices
Chapter 2 - Cardiovascular System Primary Care Prescribing Formulary - Preferred Drug Choices Drug group Drug choice Comments/notes Cardiac glycosides Thiazide diuretics Loop diuretics Aldosterone antagonist
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationCholesterol. Medicines To Help You
Medicines To Help You Cholesterol Use this guide to help you talk to your doctor, pharmacist, or nurse about your cholesterol medicines. The guide lists all of the FDA-approved products now available to
More informationDrug drug interactions highlighting P450 Cytochromes. Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017
Drug drug interactions highlighting P450 Cytochromes Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017 Financial Disclosures and Conflicts I have no financial disclosures nor conflicts concerning
More informationPharmacogenomics: application to the management of cardiovascular disease
Pharmacogenomics: application to the management of cardiovascular disease Julie A. Johnson, Pharm.D. 1, Larisa H. Cavallari, Pharm.D. 2, Amber L. Beitelshees, Pharm.D., MPH 3, Joshua P. Lewis, Ph.D. 3,
More informationObjecEves' PharmaceuEcal'Care' 9/25/16' Excellence'in'Hospice'Pharmaceu3cal'Care:' Right'Drug,'Right'Dose,'Right'Now'!'
ExcellenceinHospicePharmaceu3calCare: RightDrug,RightDose,RightNow! MaryMihalyo,PharmD,CGP,BCPS,CDE DeltaCareRx OregonHospice&PalliaEveCareAssociaEon September26,2016 ObjecEves DefinepharmaceuEcalcare.
More informationClinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19
Clinical Policy: (Zetia) Reference Number: CP.PMN.78 Effective Date: 02.01.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationJoshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
More informationAdditional Standard Generics HSA Preventive Drug List Effective January 1, 2019
Additional Standard Generics HSA Preventive Drug List Effective January 1, 2019 Employers can elect to include an additional generic HSA Preventive Drug coverage feature with your prescription benefit
More informationChapter 2 ~ Cardiovascular system
Chapter 2 ~ Cardiovascular System: General Section 1 of 6 Chapter 2 ~ Cardiovascular system 2.1 Positive inotropic drugs 2.1.1 Cardiac glycosides DIGOXIN 2.2 Diuretics Elixir 50micrograms in 1ml Injection
More informationAdapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017
Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:
More informationPravastatin conversion to atorvastatin
P ford residence southampton, ny Pravastatin conversion to atorvastatin Pravastatin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology
More informationCardiovascular Drugs and Therapies HMG CoA a REDUCTASE INHIBITORS (available in Canada)
Trade Name Dosage Forms 10 mg, 20 mg, 40 mg, 80 mg tablets Dosing Range 10-80 mg once daily 2 Dosing Based on Desired LDL Reduction 1,2,3 HMG CoA a REDUCTASE INHIBITORS (available in Canada) LIPITOR, generics
More informationAnginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial
Angina Anginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial ischemia and pain as well as prevention of myocardial
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More information1.* Dosage. A. Adults
3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors [Developed, November 1994; Revised, October 1996; September 1997; September 1998; October 1999; November 1999; August 2000; September
More informationTHE INTERACTION BETWEEN GRAPEFRUIT AND PRESCRIPTION DRUGS
THE INTERACTION BETWEEN GRAPEFRUIT AND PRESCRIPTION DRUGS Item Type text; Electronic Thesis Authors Todd, Erin Elizabeth Publisher The University of Arizona. Rights Copyright is held by the author. Digital
More informationCHAPTER 2. Knowing YOUR MEDICATIONS. Image: istock.com/bakibg. Knowing Your Medications 23
CHAPTER 2 Knowing YOUR MEDICATIONS Knowing Your Medications 23 Image: istock.com/bakibg MEDICATION Prescription medications help your heart get better and protect you from more harm. People who take their
More informationDiabetes Complications Guideline Based Screening, Management, and Referral
Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes
More informationPraluent. Praluent (alirocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.06 Subject: Praluent Page: 1 of 10 Last Review Date: September 20, 2018 Praluent Description Praluent
More informationCardiovascular Risk Reduction in Diabetic Mellitus. Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist
Cardiovascular Risk Reduction in Diabetic Mellitus Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist Cardiovascular Risk Reduction in Diabetic Mellitus Disclosures
More informationChest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted
Patient Name: Diagnosis: Allergies with reaction type: Chest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted
More informationCardiovascular Pharmacology 2013
Cardiovascular Pharmacology 2013 Mary M. Bridgeman, Pharm.D.,., BCPS, CGP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers University Which medication should be prescribed for a patient
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationYour Kailos Test. Sample ID: CL-4194-DM. Jane Doe DOB: Hello Jane,
1 Jane Doe DOB: 1985-01-05 Sample ID: CL-4194-DM Hello Jane, Thank you for ordering your Kailos test for antidepressants. Kailos Genetics is committed to making gene-based healthcare available to YOU.
More informationVerapamil to diltiazem conversion
Verapamil to diltiazem conversion Search CALCIUM CHANNEL BLOCKER DOSING. diltiazem should not exceed 240 mg a day;. Verapamil is a CYP3A4 moderate inhibitor and sensitive substrate; 01/04/2018 Brahmin
More informationDiagnosis: Allergies with reaction type:
Patient Name: Diagnosis: Allergies with reaction type: ICU Stroke-Ischemic S/P tpa Version 2 5/29/14 This order set is designed to be used with an admission set or for a patient already admitted Nursing
More informationInstructions for use. Impact on Medications. Compilation of Genetic Results. Individual Gene Review
Date of Birth: [object Object] Test Date: 03/22/2016 Report Date: 03/22/2016 A Instructions for use PAGE 2 B Impact on Medications PAGE 3-4 C Compilation of Genetic Results PAGE 5-6 D Individual Gene Review
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationPharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT
PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationInformation for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs CADUET (amlodipine besylate/atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have
More informationUtility of Pharmacogenomics to Identify and Limit CV Risk. Christopher B. Granger, MD
Utility of Pharmacogenomics to Identify and Limit CV Risk Christopher B. Granger, MD Disclosure Research contracts: AstraZeneca, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company, and Boehringer
More informationReport generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ABCIXIMAB 2.9 Antiplatelet drugs This drug
More informationInformation for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
More informationPDF created with pdffactory trial version
We are using more prescription drugs than ever before to manage health conditions and prevent problems. And those drugs are more expensive than ever before. In 2003, prescription drug costs in the United
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationKailos Test Results Dr. Ronald McGlennen, Medical Director CLIA#: 01D
PATIENT: Doe, Jane (F) COLLECTED: 10/14/2014 SAMPLE TYPE: Buccal ACCESSION: CL-4194-DM DOB: 1985-01-01 RECEIVED: 12/30/2015 PHYSICIAN: Dr. RONALD C MCGLENNEN PATIENT ID: REPORTED: 12/30/2015 PRACTICE:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vytorin) Reference Number: CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationPharmacy Costs: Can I Make a Difference?
Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,
More informationRxIGHT RESULTS REPORT Pharmacogenetics Test Results
Authorizing Physician: Dr. Denis Patterson, DO Patient Name: John Williams Account ID: 123456 Patient SSN: xxx-xx-xxxx Requisition ID: RXT00006 Patient DOB: 12/1/1949 Collected: Received: Analyzed: Completed:
More informationTREAT HEART DISEASE. Taking your heart medicines
TREAT HEART DISEASE Taking your heart medicines Cardiovascular Prevention & Rehabilitation Program Dr. Paul Oh, Medical Director Nicole Sandison, Advanced Practice Leader Valerie Skeffington, Program
More informationOver the last 50 years, the scientific and medical community has
Precision medicine and pharmacogenomics in community and primary care settings Over the last 50 years, the scientific and medical community has seen the field of pharmacogenomics and precision medicine
More informationGeneDose Genetic Response Report
ISPM Labs d/b/a Capstone Diagnostics 8601 Dunwoody Pl, Ste 444 Atlanta GA 30350 Phone: (678) 515-4524 Fax: (470) 355-5462 Laboratory Director: John Hanson, PhD CLIA ID Number: 11D2073885 http://www.capstonediagnostics.com
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationCrestor and thyroid problems
Recently it has been observed that many people on statins have been referred for special radioiodine studies because they have been found to have low to no thyroid stimulating hormone (TSH) in their blood
More informationAtrial fibrillation. Understanding NICE guidance
Understanding NICE guidance Information for people who use NHS services Atrial fibrillation NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and the treatments
More informationBeta-blockers. Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol.
Drugs of CVS Beta-blockers Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol. Atenolol.cardioselective Propranolol, nonselective Bisoprolol, cardioselective Metoprolol Carvedilol, alpha
More information2. Cardiovascular System
1 2. Cardiovascular System 2.1 - Positive inotropic drugs 2.1.1 Cardiac glycosides Digoxin H - Digoxin specific antibody (Digifab ) Digoxin is indicated for rate control in atrial fibrillation and as add-on
More informationACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR
S/N ME OF MEDICATIONS BRANDED/GENERIC DRUG CLASS * UNIT PRICE RANGE (SGD$) 1 ACEBUTOLOL HCL 100MG CAPSULE SECTRAL BETA BLOCKERS 0.50 2 ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS 0.33 3 ALISKIREN
More informationTreatment of Stable Coronary Artery Disease Pharmacotherapy
Treatment of Stable Coronary Artery Disease Pharmacotherapy José López-Sendón Hospital Universitario La Paz. Madrid. Spain Conflict of interest: I will discuss off label use and/or investigational use
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationPersonalized Medicine in Real Time
LABORATORY OF PERSONALIZED HEALTH LPH Personalized Medicine in Real Time DNA-Guided Clopidogrel (Plavix ) Management Pharmacogenetic Foundations and Case Study 1 Clopidogrel (Plavix ) Leading AntiPlatelet
More informationCardiovascular Drugs and Therapies BETA-ADRENERGIC RECEPTOR BLOCKING AGENTS
Generic Name Acebutolol Atenolol Bisoprolol Carvedilol Esmolol IV Trade Name Dosage Forms SECTRAL, 100 mg, 200 mg, 400 mg tablet TENORMIN, 25 mg, 50 mg, 100 mg tablet MONOCOR, 5 mg, 10 mg tablet 3.125
More informationRISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More information